South San Francisco, Calif.-based healthcare company Titan Pharmaceuticals Inc. said it was no longer in compliance with one of Nasdaq's listing requirements.
Specifically, the company has been unable to maintain a minimum bid price of $1 per share for continued listing on the stock exchange.
The company has until Nov. 26 to regain compliance, and the development has no immediate effect on the company's listing on the Nasdaq capital market.
